Cardiogenic shock is treated through a rapid, layered approach: restoring blood pressure with medications, reopening blocked arteries when a heart attack is the cause, and supporting the heart mechanically if it cannot pump enough blood on its own. Despite major advances in care, the one-year mortality rate remains between 30 and 50 percent, which makes early recognition and fast intervention critical to survival.
What Cardiogenic Shock Looks Like
Cardiogenic shock occurs when the heart suddenly cannot pump enough blood to meet the body’s needs. The hallmark is a sustained drop in systolic blood pressure to 90 mmHg or below for 30 minutes or longer, paired with signs that organs are not getting enough blood flow. Those signs include urine output dropping below 30 mL per hour, cool or mottled skin on the extremities, confusion, and a rapid heart rate as the body tries to compensate.
Doctors now classify shock severity using a five-stage system (SCAI stages A through E). Stage A means a patient is at risk but not yet in shock. Stage B is “beginning,” where blood pressure is becoming unstable but organs are still receiving adequate blood flow. True shock starts at Stage C, where there is clear evidence of organ hypoperfusion. Stage D means the patient is getting worse despite initial treatment. Stage E is refractory shock, the most severe form, where the body is no longer responding to standard interventions. This staging system helps teams communicate quickly and escalate treatment at the right time.
Medications to Stabilize Blood Pressure and Heart Function
The first priority is keeping blood pressure high enough to deliver oxygen to the brain, kidneys, and other vital organs. Two categories of drugs do the heavy lifting: vasopressors, which tighten blood vessels to raise pressure, and inotropes, which strengthen the heart’s contractions so it pushes out more blood per beat.
Norepinephrine is typically the first vasopressor used. It raises blood pressure by constricting blood vessels while also mildly boosting heart contractions. It is almost always paired with a stronger inotrope because on its own it does not improve the heart’s pumping power enough. Dobutamine is the most common inotrope, directly stimulating the heart muscle to contract more forcefully. Milrinone works through a different pathway and is generally reserved for patients whose blood pressure is not critically low (above roughly 85 mmHg), because it can cause further drops in pressure as a side effect.
These medications buy time but come with tradeoffs. They increase the heart’s oxygen demand, which can worsen injury to already-damaged heart muscle. That is why the goal is always to stabilize the patient long enough to address the underlying cause.
Emergency Revascularization for Heart Attack
The most common cause of cardiogenic shock is a massive heart attack. When a coronary artery is blocked, the section of heart muscle it feeds stops contracting, and if enough muscle is affected, the heart can no longer maintain adequate output. Reopening that artery is the single most impactful treatment.
Current guidelines from the American Heart Association and American College of Cardiology recommend emergency catheter-based intervention (PCI) as soon as possible, ideally within 90 minutes of arrival. The procedure targets only the artery responsible for the heart attack. This is an important distinction: treating multiple blocked arteries at the same time actually leads to worse outcomes. The CULPRIT-SHOCK trial found that patients who had multivessel PCI during cardiogenic shock had higher rates of death and kidney failure at both 30 days and one year compared to those who had only the culprit artery treated.
When catheter-based intervention is not feasible, emergency bypass surgery (CABG) is the alternative. The landmark SHOCK trial established that revascularization should happen within 18 hours of shock onset. In that trial, survival rates at 30 days were similar between PCI and CABG (about 56 and 57 percent, respectively). Registry data from the same trial showed a stark contrast between patients who received revascularization and those treated with medications alone: in-hospital mortality was 46 percent with PCI, 24 percent with CABG, and 78 percent with medical therapy only.
Mechanical Circulatory Support
When medications and revascularization are not enough, mechanical devices can temporarily take over part of the heart’s workload. These are used when patients are unresponsive to conventional intensive care, and earlier deployment tends to produce better results by limiting the damage that prolonged low blood flow causes to other organs.
Microaxial Flow Pumps
The most notable development in recent years involves small pump devices (such as the Impella) threaded through an artery and positioned across the heart valve. These are the only support devices that actively pull blood forward out of the heart, directly unloading the struggling ventricle. The 2025 ACC/AHA guidelines state that a microaxial flow pump is reasonable for patients with heart attack-related cardiogenic shock in SCAI stages C, D, or E who are not comatose and have blood vessels large enough to accommodate the device. However, complications including bleeding, limb loss from reduced blood flow to the leg, and kidney failure are more common with these pumps compared to standard care, so the decision requires careful case-by-case judgment. These devices cannot be used in patients with certain valve conditions, a hole between the heart chambers, severe peripheral artery disease, or conditions that prevent blood thinners.
Intra-Aortic Balloon Pump
The intra-aortic balloon pump (IABP) was for decades the default mechanical support device. A balloon in the aorta inflates and deflates in sync with the heartbeat, modestly reducing the heart’s workload and improving blood flow to the coronary arteries. European guidelines no longer recommend routine IABP use for heart attack-related cardiogenic shock, and the latest U.S. guidelines echo this, noting that studies do not support its routine use in this setting. It may still have a role in other causes of shock or during high-risk catheter procedures.
VA-ECMO
Venoarterial extracorporeal membrane oxygenation (VA-ECMO) is essentially a bedside heart-lung machine. Blood is drained from a large vein, pumped through an oxygenator, and returned to an artery. It provides both circulatory and respiratory support simultaneously, making it particularly useful in cardiac arrest or near-arrest situations where there is no time for detailed assessment, and in cases where the right side of the heart is also failing. It cannot be used in patients with significant aortic valve leakage, as it would worsen pressure buildup in the heart. Like other devices, severe peripheral artery disease is a contraindication for standard placement through leg vessels. Current guidelines do not support routine VA-ECMO use in heart attack cardiogenic shock either, but it remains an option when other approaches fail.
Breathing Support
More than half of cardiogenic shock patients develop respiratory distress, usually from fluid backing up into the lungs as the heart fails to pump it forward. About 43 percent require mechanical ventilation. Noninvasive ventilation, delivered through a mask, is recommended as the first-line approach when oxygen levels drop below 90 percent. It reduces the need for intubation and lowers early mortality compared to standard oxygen delivery.
Positive pressure ventilation offers several benefits specific to cardiogenic shock. It pushes fluid out of the air sacs, reduces the amount of blood returning to an already overloaded heart, and decreases the workload of breathing, all of which lower the heart’s oxygen demand. Caution is needed in patients with low blood pressure or right-sided heart failure, because the positive pressure can impair the right ventricle’s ability to pump blood into the lungs.
Protecting Other Organs
Cardiogenic shock does not just damage the heart. Prolonged low blood flow and venous congestion injure the kidneys, liver, brain, lungs, and gut. Roughly 10 percent of patients develop anoxic brain damage from insufficient oxygen delivery, which extends hospital stays and delays return to normal life. Delirium is common, especially in older patients, driven by a combination of low blood flow, inflammation, and stress hormones.
Kidney injury is monitored through urine output and blood tests. When creatinine levels rise to more than double the patient’s baseline or urine output remains critically low, continuous kidney replacement therapy (a slow, gentle form of dialysis) is recommended. Liver damage shows up as a sharp spike in liver enzymes and can result from either reduced blood flow to the liver or blood backing up into it from the failing heart. There is no specific treatment for liver injury in this context other than restoring adequate circulation as quickly as possible.
This cascading organ damage is a major reason why speed matters so much in cardiogenic shock treatment. Every hour of inadequate blood flow compounds the injury across multiple organ systems, making recovery progressively harder even if the heart itself is eventually stabilized. Data from the past five decades show that despite all advances in technology and technique, the persistent 30 to 50 percent one-year mortality rate has not meaningfully improved, largely because organ damage accumulates before interventions can take full effect.